Apak-212 -

In cellular biology, the is a critical tumor suppressor that triggers cell cycle arrest or programmed cell death (apoptosis) in response to DNA damage. However, this process must be tightly controlled to prevent unnecessary cell death in healthy tissues.

The rise of multi‑drug‑resistant (MDR) Gram‑negative pathogens represents an urgent global health crisis. Here we report the design, synthesis, and comprehensive biological evaluation of , a 22‑residue cationic amphipathic peptide derived from a rational redesign of the native marine peptide APAK‑2 . AKAP‑212 exhibits broad‑spectrum bactericidal activity (MIC 0.5–4 µg mL⁻¹) against carbapenem‑resistant Acinetobacter baumannii , Pseudomonas aeruginosa , and Klebsiella pneumoniae while displaying negligible hemolysis (<2 % at 128 µg mL⁻¹) and low cytotoxicity toward mammalian cell lines (IC₅₀ > 200 µg mL⁻¹). Mechanistic studies indicate rapid membrane disruption via a toroidal pore model, confirmed by dye‑leakage assays, transmission electron microscopy (TEM), and solid‑state NMR. In a murine thigh infection model, a single sub‑cutanous dose of 5 mg kg⁻¹ reduced bacterial load by >3 log₁₀ CFU g⁻¹ relative to vehicle. These data position AKAP‑212 as a promising lead for development into a new class of therapeutic agents targeting MDR Gram‑negative infections. APAK-212

“Artificial construction,” Ilya said. He touched the glass, and his fingers came away rainbowed. “But old. Older than the Gateway markers.” In cellular biology, the is a critical tumor

The research highlights hidden value in "low attention" channels where audiences might be more open to being sold to, even if they aren't "glued" to the screen in a traditional sense [1]. Audience Categorisation Here we report the design, synthesis, and comprehensive